Sensus Healthcare (NASDAQ:SRTS) Given “Buy” Rating at HC Wainwright

HC Wainwright restated their buy rating on shares of Sensus Healthcare (NASDAQ:SRTS) in a research report released on Monday morning, Benzinga reports. The brokerage currently has a $8.00 target price on the stock. HC Wainwright also issued estimates for Sensus Healthcare’s Q4 2023 earnings at $0.08 EPS, FY2023 earnings at ($0.14) EPS, Q1 2024 earnings at ($0.03) EPS, Q2 2024 earnings at $0.00 EPS, Q3 2024 earnings at ($0.01) EPS and FY2024 earnings at $0.04 EPS.

Sensus Healthcare Price Performance

Shares of Sensus Healthcare stock opened at $2.10 on Monday. The stock has a 50-day moving average price of $2.45 and a 200 day moving average price of $2.87. Sensus Healthcare has a 1 year low of $1.79 and a 1 year high of $9.62.

Sensus Healthcare (NASDAQ:SRTS) last issued its earnings results on Thursday, November 9th. The company reported ($0.09) earnings per share for the quarter, missing the consensus estimate of ($0.01) by ($0.08). Sensus Healthcare had a negative return on equity of 1.93% and a negative net margin of 3.58%. The firm had revenue of $3.90 million during the quarter, compared to analyst estimates of $6.04 million. On average, equities analysts forecast that Sensus Healthcare will post -0.17 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other news, CEO Joseph C. Sardano bought 10,000 shares of the company’s stock in a transaction on Thursday, September 14th. The shares were bought at an average cost of $2.88 per share, with a total value of $28,800.00. Following the transaction, the chief executive officer now directly owns 1,175,293 shares in the company, valued at approximately $3,384,843.84. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Insiders own 11.10% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the stock. Advisor Group Holdings Inc. increased its holdings in shares of Sensus Healthcare by 313.0% during the 4th quarter. Advisor Group Holdings Inc. now owns 5,600 shares of the company’s stock valued at $41,000 after acquiring an additional 4,244 shares during the last quarter. Barclays PLC increased its holdings in shares of Sensus Healthcare by 718.5% during the 4th quarter. Barclays PLC now owns 6,319 shares of the company’s stock valued at $47,000 after acquiring an additional 5,547 shares during the last quarter. Victory Capital Management Inc. acquired a new position in shares of Sensus Healthcare during the 4th quarter valued at about $48,000. Rockefeller Capital Management L.P. increased its holdings in shares of Sensus Healthcare by 75.0% during the 4th quarter. Rockefeller Capital Management L.P. now owns 7,000 shares of the company’s stock valued at $51,000 after acquiring an additional 3,000 shares during the last quarter. Finally, BNP Paribas Arbitrage SNC acquired a new position in shares of Sensus Healthcare during the 3rd quarter valued at about $94,000. Institutional investors and hedge funds own 20.56% of the company’s stock.

Sensus Healthcare Company Profile

Sensus Healthcare, Inc, a medical device company, manufactures and sells radiation therapy devices to healthcare providers worldwide. The company uses superficial radiation therapy (SRT), a low-energy X-ray technology in its portfolio of treatment devices. It offers SRT-100, a photon X-ray low energy superficial radiotherapy system that provides patients an alternative to surgery for treating non-melanoma skin cancers, including basal cell and squamous cell skin cancers, as well as other skin conditions, such as keloids; and SRT-100 Vision, which provides the user with a superficial radiation therapy-tailored treatment planning application that integrates the embedded high frequency ultrasound imaging module, volumetric tumor analysis, beam margins planning, and dosimetry parameters.